Literature DB >> 12949728

Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice.

Martin Wagner1, Peter Fickert, Gernot Zollner, Andrea Fuchsbichler, Dagmar Silbert, Oleksiy Tsybrovskyy, Kurt Zatloukal, Grace L Guo, John D Schuetz, Frank J Gonzalez, Hanns-Ulrich Marschall, Helmut Denk, Michael Trauner.   

Abstract

BACKGROUND & AIMS: Cholestasis induces changes in hepatic adenosine triphosphate-binding cassette (ABC) transporter expression. We aimed to investigate the role of the nuclear bile acid receptor (farnesoid X receptor [FXR]) in mediating changes in ABC transporter expression and in determining liver injury.
METHODS: Hepatic ABC transporter (multidrug resistance-associated proteins [Mrp] 2-4 and bile salt export pump [Bsep]) expression and localization were studied in common bile duct-ligated (CBDL) FXR knockout (FXR(-/-)), wild-type (FXR(+/+)), and sham-operated mice. Serum alanine aminotransferase, alkaline phosphatase, bilirubin and bile acid levels, hepatic bile acid composition, and liver histology were investigated. Cholangiomanometry and bile duct morphometry were performed.
RESULTS: CBDL induced expression of Mrp 3 and Mrp 4 in FXR(+/+) and even more in FXR(-/-), whereas Mrp 2 expression remained unchanged. Bsep expression was maintained in CBDL FXR(+/+) but remained undetectable in CBDL FXR(-/-). Alanine aminotransferase levels and mortality rates did not differ between CBDL FXR(+/+) and FXR(-/-). CBDL increased biliary pressure and induced bile ductular proliferation and bile infarcts in FXR(+/+), whereas FXR(-/-) had lower biliary pressures, less ductular proliferation, and developed disseminated liver cell necroses.
CONCLUSIONS: Overexpression of Mrp 3 and Mrp 4 in CBDL mice is FXR independent and could play an important role in the adaptive hepatic ABC transporter response to cholestasis. Maintenance of Bsep expression strictly depends on FXR and is a critical determinant of the cholestatic phenotype. Lack of bile infarcts in CBDL FXR(-/-) suggests that development of bile infarcts is related to bile acid-dependent bile flow and biliary pressure. This information is relevant for the potential use of FXR modulators in the treatment of cholestatic liver diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12949728     DOI: 10.1016/s0016-5085(03)01068-0

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  90 in total

1.  Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1.

Authors:  Chan Gyu Lee; Young Woo Kim; Eun Hyun Kim; Zhipeng Meng; Wendong Huang; Se Jin Hwang; Sang Geon Kim
Journal:  Gastroenterology       Date:  2012-01-18       Impact factor: 22.682

2.  Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation.

Authors:  Anna Baghdasaryan; Thierry Claudel; Astrid Kosters; Judith Gumhold; Dagmar Silbert; Andrea Thüringer; Katharina Leski; Peter Fickert; Saul J Karpen; Michael Trauner
Journal:  Gut       Date:  2010-04       Impact factor: 23.059

3.  Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice.

Authors:  Peter Fickert; Andrea Fuchsbichler; Hanns-Ulrich Marschall; Martin Wagner; Gernot Zollner; Robert Krause; Kurt Zatloukal; Hartmut Jaeschke; Helmut Denk; Michael Trauner
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

4.  Aryl hydrocarbon receptor ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin enhances liver damage in bile duct-ligated mice.

Authors:  Jun Ozeki; Shigeyuki Uno; Michitaka Ogura; Mihwa Choi; Tetsuyo Maeda; Kenichi Sakurai; Sadanori Matsuo; Sadao Amano; Daniel W Nebert; Makoto Makishima
Journal:  Toxicology       Date:  2010-11-21       Impact factor: 4.221

5.  Nuclear factor-E2-related factor 2 expression in liver is critical for induction of NAD(P)H:quinone oxidoreductase 1 during cholestasis.

Authors:  Lauren M Aleksunes; Angela L Slitt; Jonathan M Maher; Matthew Z Dieter; Tamara R Knight; Michael Goedken; Nathan J Cherrington; Jefferson Y Chan; Curtis D Klaassen; José E Manautou
Journal:  Cell Stress Chaperones       Date:  2006       Impact factor: 3.667

6.  A nuclear receptor ligand down-regulates cytosolic phospholipase A2 expression to reduce bile acid-induced cyclooxygenase 2 activity in cholangiocytes: implications of anticarcinogenic action of farnesoid X receptor agonists.

Authors:  Daisuke Komichi; Susumu Tazuma; Tomoji Nishioka; Hideyuki Hyogo; Kazuaki Chayama
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

Review 7.  Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.

Authors:  Gustav Paumgartner
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 8.  The bile salt export pump: molecular properties, function and regulation.

Authors:  Marco Arrese; Meenakshisundaram Ananthanarayanan
Journal:  Pflugers Arch       Date:  2004-07-24       Impact factor: 3.657

Review 9.  The Farnesoid X Receptor (FXR) as modulator of bile acid metabolism.

Authors:  Folkert Kuipers; Thierry Claudel; Ekkehard Sturm; Bart Staels
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

10.  Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge.

Authors:  Joo-Youn Cho; Tsutomu Matsubara; Dong Wook Kang; Sung-Hoon Ahn; Kristopher W Krausz; Jeffrey R Idle; Hans Luecke; Frank J Gonzalez
Journal:  J Lipid Res       Date:  2009-11-09       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.